Clinical note: 1–3 mcg/kg/min (dopaminergic renal effect, no proven clinical benefit), 3–10 mcg/kg/min (β1 inotropic effect with ↑ cardiac output and risk of tachycardia), >10–20 mcg/kg/min (α1 vasopressor effect with ↑ SVR and MAP, higher risk of arrhythmias and ischemia).

Clinical note: Start at 5–10 mcg/min. Titrate according to blood pressure and symptoms. Maximum dose: 200 mcg/min.

Clinical note: 0.3–10 mcg/kg/min. Protect from light. Risk of cyanide and thiocyanate toxicity.

Clinical note: Maximum dose: 2 mg/min. Monitor heart rate, blood pressure, and bronchospasm.

Clinical note: 2–20 mcg/kg/min. Monitor heart rate and arrhythmias.

Clinical note: 0.125–0.75 mcg/kg/min. Adjust dose in renal impairment.

Clinical note: Typical infusion range 0.05–0.2 mcg/kg/min. Avoid bolus in hypotensive patients.

Clinical note: 0.5–5 mg/kg/h. Monitor for hypotension, hypertriglyceridemia, and PRIS (Propofol Infusion Syndrome).

Clinical note: 0.1–0.5 mg/kg/h (analgesia), 0.5–2.5 mg/kg/h (sedation).

Clinical note: 0.2–1.5 mcg/kg/h. Monitor for bradycardia and hypotension.

Clinical note: 0.5–5 mcg/kg/h. Monitor for respiratory depression and chest wall rigidity.

Clinical note: Dose range 0.01–0.1 mg/kg/h. Use caution or avoid in renal failure due to active metabolite accumulation.

Clinical note: 0.05–2 mcg/kg/min. Rapid onset and ultra–short context-sensitive half-life.

Clinical note: Continuous infusion range 2–20 mcg/kg/min.